Present Position: Division Head, Haematology/Oncology

Women’s Auxiliary Millennium Chair in Haematology/Oncology

Director, Garron Family Cancer Centre

Senior Associate Scientist, Research Institute

The Hospital for Sick Children

Professor of Paediatrics, University of Toronto

 

Degrees, Diplomas, Licensures and Certifications

 

1976 – 1977 Tulane University, New Orleans, LA

1977 – 1980 B.Sc. (cum laude), Southwestern at Memphis, Memphis, TN

1980 – 1984 M.D., Vanderbilt University School of Medicine, Nashville, TN

1984 – 2013 Tennessee Medical License No. MD017986

1984 National Board of Medical Examiners No. 293511

1989 American Board of Pediatrics No. 39275

1992 American Board of Pediatrics, Sub-board of Pediatric Hematology-Oncology No. 1056 (recertified 1999, 2006)

2010 - present College of Physicians and Surgeons of Ontario Reg. 94311

 

 

Specialty Training

 

1984 – 1987 Paediatric Resident, Vanderbilt University Medical Center, Nashville, TN

 

 

Fellowships

 

1987 – 1988 Research Fellow, Genetics, Vanderbilt University Medical Center, Nashville, TN

Supervisor:  Dr. John Phillips

1988 – 1990 Clinical Fellow, Paediatric Haematology/Oncology, Vanderbilt University Medical Center, Nashville, TN

Supervisor: Dr. John Lukens

 

APPOINTMENTS

 

University Appointments

 

1991 – 1997 Assistant Professor, Pediatric Hematology/Oncology, Vanderbilt University School of Medicine, Nashville, TN

1997 – 2006 Associate Professor, Pediatric Hematology/Oncology, Vanderbilt University School of Medicine, Nashville, TN

1997 – 2010 Division Chief, Pediatric Hematology/Oncology, Vanderbilt University School of Medicine, Nashville, TN

1997 – 2010 Craig-Weaver Professor of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN

2006 – 2010 Professor of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN

2010 – Present Professor of Paediatrics, University of Toronto, Toronto, ON

 

 

Hospital Appointments

 

1991 – 2010 Staff Physician, Vanderbilt University Hospital/ Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN

2010 – Present Division Head, Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON

2010 – Present Senior Associate Scientist, Child Health Evaluative Sciences Program, The Hospital for Sick Children Research Institute, Toronto, ON

2010 – Present Women's Auxiliary Millennium Chair in Haematology/Oncology, The Hospital for Sick Children, Toronto, ON

2011 – Present Director, Garron Family Cancer Centre, The Hospital for Sick Children, Toronto, ON

 

 

HONOURS AND AWARDS RECEIVED

 

1976 National Merit Scholar

1977 CRC Outstanding Freshman Chemistry Student.  

1977 Phi Eta Sigma Freshman Honor Society.  

1980 Mortar Board Honor Society (President).  

1980 Omicron Delta Kappa Honor Society.  

1980 Phi Beta Kappa Honor Society.  

1987 David T. Karzon award (outstanding resident research, VUMC Pediatrics).  

1995 Alpha Omega Alpha Medical Honor Society, alumni member.  

1996 Listed in The Best Doctors in America (Midwest Region).  

1998 Listed in The Best Doctors in America.  

2001 Listed in The Best Doctors in America.  

2002 Spirit of Gilda Award (Gilda's Club).  

2003 VUMC Dept. Pediatrics Excellence in Resident Education award.  

2003-05 Invited speaker, VUSM Pediatric Interest Group

2005 Listed in The Best Doctors in America.  

2005 Program ranked No. 7 for Cancer Care in Child Magazine survey.  

2006 Listed in America's Top Doctors (Castle Connolly).  

2006 Listed in America's Top Doctors for Cancer, 2nd ed. (Castle Connolly).  

2006 Listed in Nashville's Top Doctors.  

2006 Listed in The Best Doctors in America.  

2007 Listed in America's Top Doctors for Cancer, 3rd ed. (Castle Connolly).  

2007 Listed in The Best Doctors in America.  

2007 Vanderbilt Medical Group/ Professional Research Consultants Five Star Customer Service Award (individual - top 10% nationally).  

2007 Vanderbilt Medical Group/ Professional Research Consultants Five Star Customer Service Award (Ped. Hematology/Oncology clinic - top 10% nationally).  

2007 Vanderbilt Medical Group/ Professional Research Consultants Five Star Customer Service Award (Ped. Hematology/Oncology inpatient unit - top 10% nationally).  

2008 Listed in America's Top Doctors (Castle Connolly).  

2008 Listed in America's Top Doctors for Cancer, 4th ed. (Castle Connolly).  

2008 Listed in Nashville's Top Doctors.  

2008 Listed in The Best Doctors in America.  

2008 Vanderbilt Medical Group/ Professional Research Consultants Five Star Customer Service Award (Ped. Hematology/Oncology clinic - top 10% nationally).  

2008 Vanderbilt Medical Group/ Professional Research Consultants Five Star Customer Service Award (Ped. Hematology/Oncology inpatient unit - top 10% nationally).  

2009 Listed in America's Top Doctors (Castle Connolly).  

2009 Listed in America's Top Doctors for Cancer, 5th ed. (Castle Connolly).  

2009 Listed in The Best Doctors in America.  

2009 Vanderbilt Children's Cancer Program ranked in Top 25 U.S. News & World Report children's cancer programs.  

2010 Listed in America's Top Doctors (Castle Connolly).  

2010 Listed in America's Top Doctors for Cancer, 6th ed. (Castle Connolly).  

2010 Vanderbilt Medical Group/ Professional Research Consultants Five Star Customer Service Award (individual - top 10% nationally).  

2010 Vanderbilt Medical Group/ Professional Research Consultants Five Star Customer Service Award (Ped. Hematology/Oncology clinic - top 10% nationally).  

2010 Vanderbilt Medical Group/ Professional Research Consultants Five Star Customer Service Award (Ped. Hematology/Oncology inpatient unit - top 10% nationally).  

2011 Listed in America's Top Doctors (Castle Connolly).  

2011 Listed in America's Top Doctors for Cancer, 7th ed. (Castle Connolly).  

2012 Listed in America's Top Doctors (Castle Connolly).  

2012 Listed in America's Top Doctors for Cancer, 8th ed. (Castle Connolly).  

 

 

PUBLICATIONS

 

PA-denotes Principal Author; SRI-Senior Responsible Investigator; CPA-Co-Principal Author; C-Collaborator

 

Peer Reviewed - Journal Publications

 

Published and In Press

 

1. Giannone L, Whitlock JA, Dev VG, Wolff SA: Use of the BCR probe to demonstrate extramedullary recurrence of CGL with a T cell lymphoid phenotype following bone marrow transplantation.  Bone Marrow Transplantation 1988: 3: pp 631-636.  CPA

 

2. Whitlock JA, Janco RL: Management of protein S deficiency [letter].  Journal of Pediatrics 1988: 112: pp 1050-1051.  PA

 

3. Devore R, Whitlock JA, Hainsworth JD, Johnson DH: Therapy-related acute nonlymphocytic leukemia with monocytic features and rearrangement of chromosome 11q. Annals of Internal Medicine .  Annals of Internal Medicine 1989: 110: pp 740-742.  CPA

 

4. Kinney MC, Collins RD, Whitlock JA, Cousar JB, Vogler LB: Response of neoplasms of B cell lineage to the proliferative effects of B cell growth factor and the phorbol ester TPA. American Journal of Pathology 1989: 134: pp 913-923.  C

 

5. Whitlock JA, Janco RA, Phillips JA: Inherited hypercoagulable states in children.  American Journal of Pediatric Hematology/Oncology 1989: 11: pp 170-173.  PA

 

6. Whitlock JA, Janco RL: The development of deep venous thromboses (DVT) in three pilots [letter].  Aviat Space Environ Med 1990: 61: pp 443.  PA

 

7. Whitlock JA, Greer JP, Lukens JN: Epipodophyllotoxin-related leukemia: Identification of a new subset of secondary leukemias.  Cancer 1991: 68: pp 600-604.  PA

 

8. Bosque PJ, Vnencak-Jones CL, Johnson M, Whitlock J, McLean M: A PrP codon 178 base substitution and a 24-bp interstital deletion in familial Creutzfeldt-Jakob disease.  Neurology 1992: 42: pp 1864-1870.  C

 

9. Olsen JE, Winston JT, Whitlock JA, Pledger WJ: Cell cycle-dependent gene expression in V point-arrested BALB/c-3T3 cells.  J Cell Physiol 1992: 154: pp 333-342.  C

 

10. Tharapel SA, Vnencak-Jones CL, Whitlock JA, Jain R: Molecular confirmation of BCR-ABL fusion in a chronic myeloid leukemia with a complex translocation involving chromsomes 9, 15 and 22.  Genes, Chromosomes and Cancer 1992: 4: pp 343-345.  C

 

11. Whitlock JA, McCurley TL: Acute lymphocytic leukemia with variant t(5;14) and preleukemia: Expanding the spectrum of the 5q- abnormality? [letter].  Blood 1992: 79: pp 1376-1377.  PA

 

12. Kinney MC, Collins RD, Greer JP, Whitlock JA, Sioutos N, Kadin ME: A small cell predominant variant of primary Ki-1 (CD30)+ T cell lymphoma.  Amer J Surg Pathol 1993: 17: pp 859-868.  C

 

13. Whitlock JA: Etoposide for Langerhans cell histiocytosis [letter].  Med Pediatr Oncol 1993: 21: pp 379.  PA

 

14. Whitlock JA, McCurley T: Childhood acute lymphocytic leukemia with a preleukemic phase: Report of an associated translocation and review of the literature.  Leukemia and Lymphoma 1993: 11: pp 299-303.  PA

 

15. Hord JD, Whitlock JA, Grossman DJ: Immune thrombocytopenic purpura in infants.  Arch Pediatr Adolesc Med 1994: 148: pp 333-334.  CPA

 

16. Whitlock JA, Raimondi SC, Harbott J, Morris SW, McCurley TL, Hansen-Hagge TE, Ludwig WD, Weimann G, Bartram CR: t(5;14)(q33-34;q11): A new recurring cytogenetic abnormality in childhood acute leukemia.  Leukemia 1994: 8: pp 1539-1543.  PA

 

17. Hord JD, Gay JC, Whitlock JA, Janco RL, Edwards JR, Greer JP, Lukens JN: Long-term granulocyte-macrophage colony-stimulating factor and immunosuppression in the treatment of acquired severe aplastic anemia.  Journal of Pediatric Hematology/Oncology 1995: 17: pp 140-144.  C

 

18. Hord JD, Whitlock JA, Gay JC: Thrombocytopenia in neonates with trisomy 21.  Arch Pediatr Adolesc Med 1995: 149: pp 824-825.  CPA

 

19. Martincic D, Whitlock JA: Improved detection of p53 point mutations by dideoxy fingerprinting (ddF).  Oncogene 1996: 13: pp 2039-2044.  SRI

 

20. Dasouki M, Jurecic V, Phillips JA, Whitlock JA, Baldini A: DiGeorge anomaly and chromosome 10p deletions: One or two loci? American Journal of Medical Genetics 1997: 73: pp 72-75.  C

 

21. Ford C, Whitlock JA, Pietsch JB: Glutamine-supplemented tube feedings versus total parenteral nutrition in children receiving intensive chemotherapy.  J Ped Onc Nurs 1997: 14: pp 68-72.  SRI

 

22. Hord JD, Whitlock JA, Gay JC, Lukens JN: Clinical features of myelokathexis and  treatment with hematopoietic cytokines: A case report of two patients and review of the literature.  Journal of Pediatric Hematology/Oncology 1997: 19: pp 443-448.  SRI

 

23. Jennings MT, Hart CE, Commers PA, Whitlock JA, Martincic D, Maciunas RJ, Moots PL, Shehab TM: Transforming growth factor beta as a potential tumor progression factor among hyperdiploid glioblastoma cultures: Evidence for the role of platelet-derived growth factor.  Journal of Neuro-Oncology 1997: 31: pp 233-254.  C

 

24. Koury MJ, Park DJ, Martincic D, Horne DW, Kravtsov V, Whitlock JA, del Pilar Aguinaga MP, Kopsombut P: Folate deficiency delays the onset but increases the incidence of leukemia in Friend virus-infected mice.  Blood 1997: 90: pp 4054-4061.  C

 

25. Whitlock JA, Wells RJ, Hord JD, Janco RL, Greer JP, Gay JC, Edwards JR, McCurley TL, Lukens JN: High dose cytosine arabinoside and etoposide: an effective regimen without anthracyclines for refractory childhood acute nonlymphocytic leukemia.  Leukemia 1997: 11: pp 185-189.  PA

 

26. Kravtsov VD, Greer JP, Whitlock JA, Koury MJ: Use of the microculture kinetic assay of apoptosis to determine chemosensitivities of leukemias.  Blood 1998: 92: pp 968-980.  C

 

27. Felix CA, Hosler MR, Slater DJ, Parker R, Masterson M, Whitlock JA, Rebbeck TR, Nowell PC, Lange BJ: MLL genomic breakpoint distribution within the breakpoint cluster region in de novo leukemia in children.  Journal of Pediatric Hematology/Oncology 1998: 20: pp 299-308.  C

 

28. Martincic D, Zimmerman SA, Ware RE, Sun MF, Whitlock JA, Gailani D: Identification of mutations and polymorphisms in the factor XI genes of an African American family by dideoxyfingerprinting.  Blood 1998: 92: pp 3309-3317.  C

 

29. Thapa PB, Whitlock JA, Brockman Worrell KG, Gideon P, Mitchell EF, Roberson P, Pais R, Ray WA: Prenatal exposure to metronidazole and risk of childhood cancer: A retrospective cohort study of children younger than 5 years.  Cancer 1998: 83: pp 1461-1468.  CPA

 

30. Arico M, Nichols K, Whitlock JA, Arceci R, Haupt R, Mittler U, K'fchne T, Lombardi A, Ishii E, Egeler RM, Danesino C: Familial clustering of Langerhans cell histiocytosis.  Brit J Haematology 1999: 107: pp 883-888.  C

 

31. Frangoul H, Ames MM, Mosher RB, Reid JM, Krailo MD, Siebel NL, Shaw DW, Steinherz PG, Whitlock JA, Holcenberg JS: Phase I study of topotecan administered as a 21-day continuous infusion in children with recurrent solid tumors: A report from the Children's Cancer Group.  Clinical Cancer Research 1999: 5: pp 3956-3962.  C

 

32. Martincic D, Koury MJ, Gale, K, Whitlock JA: Detection of mutations by automated fluorescence/RNA-based dideoxy fingerprinting (ArddF).  Oncogene 1999: 18: pp 617-621.  SRI

 

33. Pietsch JB, Ford C, Whitlock JA: Management of pleural effusions in children with mediastinal lymphoma.  Journal of Pediatric Surgery 1999: 34: pp 635-638.  C

 

34. Pietsch JB, Ford C, Whitlock JA: Nasogastric tube feedings in children with high risk cancer: A pilot study.  Journal of Pediatric Hematology/Oncology 1999: 21: pp 111-114.  C

 

35. Weitzman S, Wayne A, Arceci R, Lipton J, von der Weid N, De Rossi G, Haupt R, Pitel P, Tan C, McClain K, Whitlock J: Nucleoside analogues in the therapy of Langerhans cell histiocytosis: A survey of members of the Histiocyte Society and review of the literature.  Medical and Pediatric Oncology 1999: 33: pp 476-481.  C

 

36. Megonigal MD, Rappaport EF, Wilson RB, Jones DH, Lange BJ, Whitlock JA, Ortega JA, Slater DJ, Nowell PC, Felix CA, Panhandle PCR for cDNA: A rapid method for isolation of MLL fusion transcripts involving unknown partner genes. Proc Nat Acad Sci.  Proc Nat Acad Sci 2000: 97: pp 9597-9602.  C

 

37. Suara R, Whitlock J, Spearman P: Mycobacteria fortuitum central venous catheter-related bacteremia in an infant with renal sarcoma.  Journal of Pediatric Hematology and Oncology 2001: 18: pp 363-365.  C

 

38. Tarumi T, Martincic D, Whitlock JA, Addy JH. Williams SM. Gailani D: Conserved worldwide linkage disequilibrium in the human factor XI gene.  Genomics 2001: 70: pp 269-272.  C

 

39. France DJ, Miles P, Cartwright J, Patel N, Ford C, Edens C, Whitlock JA: A chemotherapy incident reporting and improvement system. The Joint Commission Journal on Quality and Safety.  Journal on Quality and Safety 2002: 29: pp 171-180.  SRI

 

40. Hansen-Hagge TE, Schafer M,  Kiyoi H, Morris SW, Whitlock JA, Koch P, Bohlmann I, Mahotka C, Bartram CR, Janssen JWG: Disruption of the RanBP17/Hox11L2 region by recombination with the TCRd locus in acute lymphoblastic leukemias with t(5;14)(q33-34;q11).  Leukemia 2002: 16: pp 2205-2212.  C

 

41. Halasa NB, Whitlock JA, McCurley TL, Smith JA, Zhu Q, Ochs H, Dermody TS, Crowe JE Jr: Fatal hemophagocytic lymphohistiocytosis associated with Epstein-Barr virus infection in a patient with a novel mutation in the signaling lymphocytic activation molecule-associated protein.  Clin Infect Dis 2003: 37: pp e136-141.  C

 

42. Wells RJ, Adams MT, Alonzo TA, Arceci RJ, Buckley J, Buxton AB, Dusenbery K, Gamis A, Masterson M, Vik T, Warkentin P, Whitlock JA: Mitoxantrone and cytarabine induction, high dose cytarabine and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia:  Children's Cancer Group study 2951.  Journal of Clinical Oncology 2003: 21: pp 2940-2947.  C

 

43. Carter BS, Howenstein M, Gilmer MJ, Throop P, France D, Whitlock JA: Circumstances surrounding deaths of hospitalized children: Opportunities for pediatric palliative care.  Pediatrics 2004: 114: pp e361-366.  C

 

44. France DJ, Cartwright J, Jones V, Thompson V, Whitlock JA: Improving pediatric chemotherapy safety through voluntary incident reporting:  Lessons from the field. Journal of Pediatric Oncology Nursing.  2004: 21: pp 200-206.  SRI

 

45. Ho RH, Johnson J, Dev VG, Whitlock JA: A novel translocation, t(2;20)(q35;p12), in embryonal rhabdomyosarcoma.  Cancer Genetics Cytogenetics 2004: 151: pp 73-77.  SRI

 

46. Bassal M, La MK, Whitlock JA, Sather HN, Heerema HA, Gaynon PS, Stork LS: Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952.  Pediatric Blood and Cancer 2005: 44: pp 21-28.  C

 

47. Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A, Bernstein M, Billett A, Kurtzberg J, Reaman G, Gaynon P, Whitlock J, Krailo M, Harris M: Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: A report from the Children's Oncology Group.  Journal of Clinical Oncology 2005: 23: pp 3376-3382.  C

 

48. Whitlock JA, Krailo M, Reid JM, Ruben SL, Ames MM, Owen W, Reaman G: A phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: A Children's Oncology Group study.  Journal of Clinical Oncology 2005: 23: pp 9179-9186.  PA

 

49. Whitlock JA, Sather HN, Gaynon P, Robison LL, Wells R, Trigg M, Heerema NA, Bhatia S: Clinical characteristics and outcome of children with Down Syndrome and acute lymphoblastic leukemia: A Children's Cancer Group study.  Blood 2005: 106: pp 4043-4049.  PA

 

50. Angiolillo A, Whitlock J, Chen Z, Zhengjia N, Krailo M, Reaman G: Phase II study of gemcitabine in children with relapsed acute lymphoblastic leukemia or acute myelogenous leukemia (ADVL0022): A Children's Oncology Group report.  Pediatric Blood and Cancer 2006: 46: pp 193-197.  C

 

51. Hawkins DS, Bradfield S, Whitlock JA, Krailo M, Franklin J, Blaney SM, Adamson P, Reaman G: Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: A Children's Oncology Group study.  Pediatric Blood and Cancer 2006: 47: pp 790-794.  C

 

52. Rhodes MM, Delbeke D, Whitlock JA, Martin W,  Kuttesch JF, Frangoul HS, Shankar S: Utility of FDG-PET/CT in follow-up of children treated for Hodgkin's and non-Hodgkin's Lymphoma.  Journal of Pediatric Hematology/Oncology 2006: 28: pp 300-306.  C

 

53. Bagatell R, Gore L, Egorin MJ, Ho R, Heller G, Boucher N, Zuhowski EG, Whitlock JA, Hunger SP, Narendran A, Katzenstein HM, Arceci RJ, Boklan JL, Herzog CE, Whitesell LJ, Ivy SP, Trippett TM: Phase I pharmacokinetic and pharmacodynamic study of 17-NAllylamino-17-Demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: A Pediatric Oncology Experimental Therapeutics Investigators Consortium study.  Clinical Cancer Research 2007: 13: pp 1783-1788.  C

 

54. Campbell LK, Scaduto M, Sharp W, Dufton L, Van Slyke D, Whitlock JA, Compas B: A meta-analysis of the neurocognitive sequelae of treatment for childhood acute lymphocytic leukemia.  Pediatric Blood and Cancer 2007: 49: pp 65-73.  C

 

55. Jones E, Koyama T, Ho RH, Kuttesch J, Shankar S, Whitlock JA, Cartwright J, Frangoul H: Safety and efficacy of a continuous infusion, patient controlled antiemetic pump for children receiving moderately or highly emetogenic chemotherapy.  Pediatric Blood and Cancer 2007: 48: pp 330-332.  C

 

56. Rhodes MM, Miller J, Sipos L, Whitlock J: ChemoDuck: The creation of an educational tool for young children with cancer.  Supportive Cancer Care 2007: 4: pp 13-16.  SRI

 

57. Stover DG, Alapati S, Regueira O, Turner C, Whitlock JA: Treatment of juvenile xanthogranuloma.  Pediatric Blood and Cancer 2008: 51: pp 130-133.  SRI

 

58. Campbell LK, Scaduto M, Van Slyke D, Niarhos F, Whitlock JA, Compas BE: Executive function, coping, and behavior in survivors of childhood acute lymphocytic leukemia.  Journal of Pediatric Psychology 2009: 34: pp 317-327.  C

 

59. Eckrich MJ, Domm J, Ho R, Whitlock JA, Frangoul H: Autologous stem cell transplant in a patient with Down syndrome and relapsed Hodgkin lymphoma.  Pediatric Blood and Cancer 2009: 53: pp 1327-1328.  C

 

60. Jayanthan A, Howard SC, Trippett T, Horton T, Horton T, Whitlock JA, Daisley L, Lewis V, Narendran A: Targeting the Bcl-2 family of proteins in Hodgkin Lymphoma: In vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737.  Leukemia and Lymphoma 2009: 50: pp 1174-1182.  C

 

61. Trippett TM, Herzog C, Whitlock JA, Wolff J, Kuttesch J, Bagatell R, Hunger SP, Boklan J, Smith AA, Arceci RJ, Katzenstein HM, Harbison C, Zhou X, Lu H, Weber M, Gore L: Phase I and Pharmacokinetic Study of Cetuximab and Irinotecan in Children with Refractory Solid Tumors: A Study of the Pediatric Oncology Experimental Therapeutic Investigators' Consortium (POETIC).  Journal of Clinical Oncology 2009: 27: pp 5102-5108.  C

 

62. Weitzman S, Arceci R, Braier J, Donadieu J, Egeler RM, Grois N, Ladisch S, Pötschger U, Webb D, Whitlock J: 2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). Results of the LCH-S-98 protocol of the Histiocyte Society. Pediatric Blood and Cancer 2009: 53: pp 1271-1276.  C

 

63. Audino AN, Blatt J, Carcamo B, Castaneda V, Dinndorf P, Wang WC, Whitlock JA, Hord JD: High-dose cyclophosphamide treatment for refractory severe aplastic anemia in children.  Pediatric Blood and Cancer 2010: 54(2): pp 269-272.  C

 

64. Horton TM, Sposto R, Brown P , Reynolds CP, Hunger SP, Winick N , Raetz EA, Carroll W, Arceci RJ, Borowitz MJ, Gaynon PS, Gore L, Jeha S, Maurer BJ, Siegel SE, Biondi A, Kearns PR, Narendran A, Silverman LB, Smith MA, Zwaan CM, Whitlock JA: Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): Review from an international consensus conference.  Pediatric Blood and Cancer 2010: 54(7): pp 872-878.  SRI

 

65. Robinson KE, Livesay KL, Campbell LK, Scaduto M, Cannistraci CJ, Anderson AW, Whitlock JA, Compas BE: Working memory in survivors of childhood acute lymphocytic leukemia: Functional neuroimaging analyses.  Pediatric Blood and Cancer 2010: 54: pp 585-590.  C

 

66. Maloney KW, Carroll WL, Carroll AJ, Devidas M, Borowitz MJ, Martin PL, Pullen J,. Whitlock JA, Willman CL, Winick NJ, Camitta BM, Hunger SP: Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: A report from the Children's Oncology Group.  Blood 2010: 116(7): pp 1045-1050.  C

 

67. Esbenshade AJ, Simmons JH, Koyama T, Koehler E, Whitlock JA, Friedman DL: Body mass index and blood pressure changes over the course of treatment of pediatric acute lymphoblastic leukemia.  Pediatric Blood and Cancer 2011: 56(3): pp 372-380.  C

 

68. Jayanthan A, Incoronato A, Singh A, Blackmore C, Bernoux D, Lewis  V, Stam S, Whitlock JA, Narendran  A: Cytotoxicity, drug combinability and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement.  Pediatric Blood and Cancer 2011: 56(3): pp 353-360.  C

 

69. Hunger SP, Loh ML, Whitlock JA, Winick NJ, Carroll WL, Devidas M, Raetz EA; COG Acute Lymphoblastic Leukemia Committee.  Children’s Oncology Group’s 2013 blueprint for research: acute lymphoblastic leukemia. Pediatric Blood and Cancer 2013: 60(6): pp 957-963.  C

 

70. Macy ME, Duncan T, Whitlock J, Hunger SP, Boklan J, Narendran A, Herzog C, Arceci RJ, Bagatell R, Trippett T, Christians U, Rolla K, Ivy SP, Gore L; Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC).  A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors. Pediatric Blood and Cancer 2013: 60(2): pp 230-236.  C

 

71. Cooper TM, Razzouk BI, Gerbing R, Alonzo TA, Adlard K, Raetz E, Gamis AS, Perentesis J, Whitlock JA.  Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): A report from the Children's Oncology Group. Pediatric Blood and Cancer 2013: 60(7): pp 1141-1147.  C

 

72. Asselin BL, Gaynon P, Whitlock JA.  Recent advances in acute lymphoblastic leukemia in children and adolescents: an expert panel discussion. Current Opinion Oncology 2013: Suppl 3: pp S1-13.  C

 

73. Izraeli S, Vora A, Zwaan CM, Whitlock J. How I treat ALL in Down's syndrome: pathobiology and management. Blood 2014: 123(1): pp 35-40.  C

 

74. Buitenkamp TD, Izraeli S, Zimmermann M, Forestier E, Heerema NA, van den Heuvel-Eibrink MM, Pieters R, Korbijn CM, Silverman LB, Schmiegelow K, Liang DC, Horibe K, Arico M, Biondi A, Basso G, Rabin KR, Schrappe M, Cario G, Mann G, Morak M, Panzer-Grümayer R, Mondelaers V, Lammens T, Cavé H, Stark B, Ganmore I, Moorman AV, Vora A, Hunger SP, Pui CH, Mullighan CG, Manabe A, Escherich G, Kowalczyk JR, Whitlock JA, Zwaan CM.  Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno Study Group. Blood 2014: 123(1): pp 70-77.  SRA

 

75. Vaiselbuh SR, Bryceson YT, Allen CE, Whitlock JA, Abla O.  Updates on histiocytic disorders. Pediatric Blood and Cancer 2014: 61(7): pp 1329-1335.  C

 

76. Cooper TM, Alonzo TA, Gerbing RB, Perentesis JP, Whitlock JA, Taub JW, Horton TM, Gamis AS, Meshinchi S, Loken MR, Razzouk BI.  AAML0523: A report from the Children’s Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia. Cancer 2014: 120(16): pp 2482-2489.  C

 

77. Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, McCastlain K, Ding L, Lu C, Song G, Ma J, Becksfort J, Rusch M, Chen SC, Easton J, Cheng J, Boggs K, Santiago-Morales N, Iacobucci I, Fulton RS, Wen J, Valentine M, Cheng C, Paugh SW, Devidas M, Chen IM, Reshmi S, Smith A, Hedlund E, Gupta P, Nagahawatte P, Wu G, Chen X, Yergeau D, Vadodaria B, Mulder H, Winick NJ, Larsen EC, Carroll WL, Heerema NA, Carroll AJ, Grayson G, Tasian SK, Moore AS, Keller F, Frei-Jones M, Whitlock JA, Raetz EA, White DL, Hughes TP, Guidry Auvil JM, Smith MA, Marcucci G, Bloomfield CD, Mrózek K, Kohlschmidt J, Stock W, Kornblau SM, Konopleva M, Paietta E, Pui CH, Jeha S, Relling MV, Evans WE, Gerhard DS, Gastier-Foster JM, Mardis E, Wilson RK, Loh ML, Downing JR, Hunger SP, Willman CL, Zhang J, Mullighan CG.  Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. New England Journal of Medicine 2014: 371(11): pp 1005-1015.  C

 

78. Raetz EA, Cairo MS, Borowitz MJ, Lu X, Devidas M, Reid JM, Goldenberg DM, Wegener WA, Zeng H, Whitlock JA, Adamson PC, Hunger SP, Carroll,WL. Re-induction chemoimmunotherapy with Epratuzumab in relapsed acute lymphoblastic leukemia (ALL):  Phase II results from Children’s Oncology Group (COG) Study ADVL04P2.  Pediatric Blood and Cancer 2015: 62(7): pp 1171-1175.  C

 

79. Chellapandian D, Shaikh F, van den Bos C, Somers GR, Astigarraga I, Jubran R, Degar B, Carret, A-S, Mandel K, Belletrutti MJ, Dix DB, Visser J, Abuhadra N, Chang T, Rollins B, Whitlock JA, Weitzman S, Abla O. Management and outcome of patients with Langerhans cell histiocytosis and single-bone CNS-risk lesions: A multi-institutional retrospective study.  Pediatric Blood and Cancer. 2015: 62(12): pp 2162-2166. C

 

80. Rubin G, Berendsen A, Crawford SM, Dommett R, Earle C, Emery J, Fahey T, Grassi L, Grunfeld E, Gupta S, Hamilton W, Hiom S, Hunter D, Lyratzopoulos G, Macleod U, Mason R, Mitchell G, Neal RD, Peake M, Roland M, Seifert B, Sisler J, Sussman J, Taplin S, Vedsted P, Voruganti, T, Walter F, Wardle J, Watson E, Weller D, Wender R, Whelan J, Whitlock J, Wilkinson C, de Wit N, Zimmermann C. The expanding role of primary care in cancer control. Lancet Oncology 2015: 16(12): pp 1231-1272.  C

 

81. Widger K, Friedrichsdorf S, Wolfe J, Liben S, Pole JD, Bouffet E, Greenberg M, Husain A, Siden H, Whitlock JA, Rapoport A. Protocol. Evaluating the impact of a nation-wide train-the-trainer educational initiative to enhance the quality of palliative care for children with cancer. BMC Palliative Care. 2016: 15(12): pp. 1-9. C

 

82. van der Sluis IM, Vrooman LM, Pieters R, Baruchel A, Escherich G, Goulden N, Mondelaers V, Sanchez de Toledo J, Rizzari C, Silverman LB, Whitlock JA. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation.  Haematologica 2016: 100(3): pp 279-285. SRI

 

 

Manuscripts Submitted

 

1. Niewerth D, Kaspers GJL, Jansen G, van Meerloo J, Zweegman S, Jenkins G, Whitlock JA, Hunger SP, Lu X, van de Ven PM, Horton TM, Cloos J. Ratios of immunoproteasome over constitutive proteasome expression indicate sensitivity to bortezomib-containing chemotherapy in pediatric relapsed acute leukemia. Submitted to Clinical Cancer Research.  C

 

2. Arceci R, Allen C, Dunkel I, Jacobsen E, Whitlock J, Vassallo R, Morris S, Portnoy A, Reedy BA, Smith D, Noble R, Murnane A, Cornfeld M, Rodriguez-Galindo C, Heaney ML, McClain K, Vaiselbuh S. A Phase 2a study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans Cell Histiocytosis. Submitted to Blood.  C

 

3. Patel S, Whitlock JA, Olivotto IA, Parliament M, Laperriere N, Bouffet E, Eisenstat DD, on behalf of The C¹⁷ Council. Needs assessment for a Pediatric Proton Therapy Program in Canada. Submitted to Canadian Medical Association Journal.  C

 

4. Rheingold SR, Tasian SK, Whitlock JA, Teachey DT, Borowitz MJ, Liu X, Ahern CH, Minard CG, Fox E, Weigel BJ, Blaney SM. A Phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukemia (ALL): a Children’s Oncology Group study (ADVL1114). Submitted to Journal of Clinical Oncology. C

 

5. von Stackelberg A, Locatelli F, Zugmaier G, Trippett TM, Rizzari C, Bader P, O’Brien MM, Bhojwani D, Schlegel PG, Borkhardt A, Rheingold SR, Cooper TM, Zwaan CM, Barnette P, Messina C, Michel G, DuBois SG, Hu K, Zhu Z, Whitlock JA. Handgretinger R, Gore L. A phase 1/phase 2 study of blinatumomab in paediatric patients with relapsed/refractory acute lymphoblastic leukaemia. Submitted to Journal of Clinical Oncology. C

 

 

Manuscripts in Preparation

 

1. Whitlock JA, Dalla-Pozza L, Goldberg J, Silverman LB, Ziegler DS, Attarbaschi A, Brown P, Gardner R, Gaynon P, Hutchinson R,  Marcus L, Messinger Y, Schultz K, van der Giessen J, Eckroth E, Locatelli F, Zwaan M, Wood B, Sposto R, Gore L:  Nelarabine in combination with etoposide and cyclophosphamide is active in first relapse of childhood T-acute lymphocytic leukemia and T-lymphoblastic lymphoma: A collaborative study of the Therapeutic Advances in Childhood Leukemia (TACL), Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC) and Innovative Therapies for Children with Cancer (ITCC) consortia. PA

 

2. Wayne AS, Shah NN, Bhojwani D, Silverman LB, Whitlock, JA, Stetler-Stevenson M, Chang L, Gao G, Opima P, Kreitman RJ, Lanasa M, Pastan I:  The anti-CD22 immunotoxin Moxetumomab Pasudotox is active in relapsed/refractory childhood acute lymphoblastic leukemia. C

 

 

Books/Chapters in Books/Proceedings

 

Published and In Press

 

1. Whitlock DW, Whitlock JA, Coates TD: Hematologic and oncologic disorders.  In:  Nursing Care of the Critically Ill Child, 2nd Edition (Hazinski, MF, eds).  Mosby Inc., Maryland Heights, Missouri 1992.  Co-PA

 

2. Greer JP, Whitlock JA, Kinney MC: Ki-1 positive lymphomas: A useful concept? In:  Cambridge Medical Reviews: Haematological Oncology, Volume 4 (Armitage J, Newland A, Keating A, eds).  Cambridge University Press, Cambridge, UK 1995: pp 89-117.  C

 

3. Whitlock JA, Gaynon PS: Acute lymphocytic leukemia.  In:  Wintrobe's Clinical Hematology, 10th edition (Wintrobe, MM, eds).  Williams and Wilkins, Baltimore, Maryland 1998: pp 2241-2271.  PA

 

4. Whitlock JA, Gaynon PS: Acute lymphoblastic leukemia in children.  In:  Wintrobe's Clinical Hematology (Wintrobe, MM, eds).  Williams and Wilkins, Baltimore, MD 2003.  PA

 

5. Weitzman S, Whitlock J: Uncommon Histiocytic Disorders - the Non-Langerhans Cell Histiocytoses.  In:  Histiocytic Disorders of Children and Adults (Weitzman S, Egeler RM, eds).  Cambridge University Press, Cambridge, UK 2005.  SRI

 

6. Whitlock JA, Gaynon PS: Acute lymphoblastic leukemia in children.  In:  Wintrobe's Clinical Hematology, 12th edition (Greer JP, Foerster J, Rodgers GM, Paraskevas F, Glader B, Arber DA, Means, Jr RT, eds).  Lippincott Williams and Wilkins, Philadelphia, PA 2008: pp 1889-1917.  PA

 

7. Whitlock JA, Horton TM: Design of early-phase trials.  In:  New Agents for the Treatment of Acute Lymphoblastic Leukaemia (Saha V, Kearns P, eds).  Springer Publishing, NY, New York 2011.  PA